Arbutus Biopharma
ABUS
91 hedge funds and large institutions have $87.6M invested in Arbutus Biopharma in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 22 closing their positions.
2.78% more ownership
Funds ownership: 27.21% → 29.99% (+2.8%)
1% more capital invested
Capital invested by funds: $86.5M → $87.6M (+$1.17M)
3% less funds holding
Funds holding: 94 → 91 (-3)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
44% less call options, than puts
Call options by funds: $2.76M | Put options by funds: $4.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.41M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.8M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.33M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.35M |
| 2 |
Morgan Stanley
New York
|
-$2.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.81M |
| 4 |
Millennium Management
New York
|
-$1.74M |
| 5 |
Two Sigma Investments
New York
|
-$1.6M |
ABUS Hedge Fund Activity: Q2 2021 in Review
91 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2021, worth a combined $87.6M — up 1.4% from $86.5M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ABUS and 19 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 22 added.
The largest buyer was BlackRock, adding an estimated $11.6M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.35M sold.
- 91 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2021, down from 94 in Q1 2021.
- Funds reported $87.6M of Arbutus Biopharma stock for Q2 2021, up 1.4% quarter-over-quarter.
- 19 funds opened new Arbutus Biopharma positions in Q2 2021 and 22 closed out, a net change of -3 holders.
- The largest Arbutus Biopharma buyer in Q2 2021 was BlackRock, an estimated $11.6M added.
- The largest Arbutus Biopharma seller in Q2 2021 was Renaissance Technologies, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2021.